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Even reference laboratories performing several hundreds of sweat tests annually diagnose a relatively small number of cystic fibrosis patients each year. The vast majority of new diagnoses are made in the first few years of life. Sweat test referrals on older children and adults may lead to problems in result interpretation, especially when sweat sodium alone is measured,' as tended to be the case in British laboratories for technical reasons. The basic defect in cystic fibrosis has now been shown to be more closely related to chloride ion channels.f Several strategies have been suggested to resolve equivocal results. These include measurement of both ions, use of their ratio or sum.! or measurement of a quantity dependent on both such as osmolality or conductivity. Fludrocortisone suppression of sodium excretion has also been reported to be helpful in adult patients."
Correspondence: Dr J M Kirk. As a result of identification of the cystic fibrosis gene on the long arm of chromosome 7 the use of DNA probes,' both direct and linked, can be used to yield further information on an individual's risk of cystic fibrosis. Use of an oligonucleotide probe for the most common mutation (~F508) has detected this mutation in 74070 of cystic fibrosis chromosomes.s Until all mutations resulting in clinically significant disease have been isolated direct DNA probes cannot be used alone for primary diagnosis in cases with no family history of cystic fibrosis.
Full clinical assessment by a physician with wide experience of cystic fibrosis patients should also be carried out before a new diagnosis is made in an older child or adult.
We were able to study a large cystic fibrosis clinic containing patients of widely varying age and disease severity. Over a 6 month period all patients were investigated by newly available DNA technology. At the same time a sweat test 145 was carried out and a full clinical assessment made, both by experienced personnel using a standardized protocol. We did not exclude any cystic fibrosis clinic attenders, and the reference data generated therefore provides a worst estimate of overlap between normal and cystic fibrosis populations. It includes some patients who have posed major diagnostic problems over the years, who represent the very group in whom alternative diagnostic strategies could potentially be most useful. We applied several proposed diagnostic criteria to these patients to determine whether alternative strategies could categorize them more effectively than sweat chloride alone.
SUBJECTS AND METHODS

Cystic fibrosis patients
One hundred and twenty-one patients attending cystic fibrosis clinics in South East Scotland had a sweat test performed, blood sampled for DNA studies, and were assessed clinically by Shwachman score. Permission to carry out these investigations was refused by only one family. Thirteen patients were less than 1 year old, 48 were 1-11 years, 18 were 12-17 years and 28 were 18 years or over.
Control patients
Each of the 112 cystic fibrosis patients with a sweat chloride ." 70 mmollL was age and sex matched to a control. Ninety-seven controls were patients who had sweat tests performed for clinical reasons over the same time period as the cystic fibrosis patients. Fifteen matched adult volunteers were used as controls for adult cystic fibrosis patients where no appropriate patient was available.
Sweat testing methods Two systems were employed, which have been shown to yield equivalent results in our hands. I Initial sweat test referrals were tested by a modified Gibson and Cooke procedure. Repeat sweat tests, and all cystic fibrosis patients had their sweat test carried out by the Wescor Macroduct system. Tests were carried out by experienced operators only.
Sodium was measured by flame photometry, and osmolality by vapour pressure osmometer as previously described." Chloride was determined by a manual colorimetric assay. Patient samples were diluted 1 in 200 with 7· 5 mmollL lithium sulphate solution (the same diluent as used for flame photometry). To O·6 mL of the diluted sweat sample was added O·2 mL of mercuric thiocyanate 4· 17 giL in methanol followed by O·2 mL ferric nitrate 202 giL in nitric acid. Both reagents were purchased from BDH Ltd (Dorset, UK) as ready to use solutions. The absorbance at 480 nm of the red ferric thiocyanate product was measured. An aqueous solution containing 75 mmollL chloride ions was used as standard. The method is linear to 80 mmol/L, and the blue Macroduct dye does not interfere chemically or spectrophotometrically.
As internal quality control we used an aqueous solution of sodium and chloride concentrations of 60 and 70 mmollL treated in the same way as freshly collected sweat for each procedure. For Gibson and Cooke sweat tests a volume equivalent to the weight of the patient's sweat was pipetted onto a pre-weighed filter paper and then analysed in parallel with the patient's sample for all subsequent steps of the procedure. For Wescor sweat tests the control sample was diluted and analysed in the same way as the patient's sample. Quality control performance was assessed over 50 tests without exclusion. For Gibson and Cooke tests the mean sodium was 61 . 0 (SD I· 3) mmollL and the mean chloride 69· 8 (SD 2· 4) mmol/L while for the Wescor method the mean sodium was 59' 6 (SD O' 7) and the mean chloride 69·0 (SD 2· 2) mmollL. Laboratory performance did not differ markedly between the two methods.
DNA haplotyping
The .1F so8 mutation in the cystic fibrosis gene was detected in genomic DNA as previously descri bed. 8 Clinical assessment Shwachman scores were calculated from assessment of case history, growth and nutrition, pulmonary findings including lung function tests, and chest X-ray findings. Hall et a/.
RESULTS
Sweat
9 used a cutoff level of 60 mmollL for sodium and 70 mmollL for chloride for children. For adults aged 18 years or over they found the chloride cutoff remained valid, but a higher sodium value of 80 mmollL was selected to separate normal and cystic fibrosis adults. A sodium/chloride ratio of < 1 is said to be confirmatory evidence for cystic fibrosis in children;' and < 1·2 in adults."
As we used a different chloride analytical method from Hall et al., a cautious approach to using their categorization was taken. We had observed that normal children almost invariably had lower chloride than sodium concentrations and therefore selected 50 mmollL, the same upper limit of normal as for sodium. Results 70 mmollL were considered abnormal, and we regarded chloride results of 50-70 mmollL as equivocal. The final criteria used for chloride were therefore the same as those used for sodium.
Sweat chloride
The cystic fibrosis population were aged from 6 weeks to 37 years, with a mean of 11· 6 years. One hundred and twelve patients had chloride concentrations ranging from 70 to 132 mmollL, with a mean of 100 mmollL. The remaining nine patients, aged 11-27 years, had chloride results in the equivocal region, from 51-69 mmollL (Table 1) . Results analysed separately for the 66 male and 55 female subjects showed no significant differences between the sexes by the unpaired
t-test.
The matched control population had initial chloride concentrations ranging from 3-53 mmol/L with a mean of 22' 5 mmol/L. Two subjects had a sweat chloride concentration greater than or equal to 50 mmol/L. No sex difference was apparent.
Figure 1 demonstrates that sweat chloride was not age-dependent in cystic fibrosis children, while normal children showed a chloride increase of 1· 6 mmollL/year. Over the age of 12 years there was no significant change in chloride in normal individuals, while the cystic fibrosis population showed a fall of O·6 mmollL/year.
Sweat sodium
The control population had a mean sodium concentration of 40·3 mmollL. Results ranged from 5-81 mmollL and 32 subjects gave values above 50 mmollL at their first test. Cystic fibrosis patients whose chloride results were above 70 mmollL had a mean sweat sodium of 103 mmol/L (range 70-132 mmollL). The nine patients with equivocal chloride results all had abnormal sodium results of 70-102 mmollL. Again no difference was demonstrated between the sexes in either population.
Sweat sodium increased by 1. 7 mmollL/year in the cystic fibrosis population, and by 3· 1 mmollL/year in the normal population up to the age of 12 years. Thereafter there was no significant change in sweat sodium with age in either population (Fig. 1 :. the youngest of the equivocal group and also had the lowest chloride level, appeared to belong to the normal population. For older patients those with equivocal chloride results could not clearly be assigned to either population by inspection of the scattergram.
A sodium/chloride ratio of < 1 is said to be supportive of a diagnosis of cystic fibrosis in children," and 1'2 has been suggested as the equivalent figure in adults> 18 years. Figure 3 confirms that this was usually the case in affected babies and young children, the group in whom sweat tests are most frequently requested. However, the ratio increased with age, as might be expected from the greater age dependency of sodium, such that all nine patients with equivocal chloride results had values > 1. Two adult patients, 4 and 8, had values less than 1·2. By inspection of Fig. 3 patients 1, 2 and 5 appeared to belong to the normal population, 3 and 7 to the cystic fibrosis population, and the remainder could not be clearly assigned to either. The sum of sodium and chloride concentrations was less than 140 in Patients 1 and 4 (Table 1) , and greater than 140 in the remainder. Of the nine patients with equivocal chloride results none was homozygous for the deletion (FF), six were heterozygous (NF) and the remaining three had no copies of this deletion (NN; Table 1 ).
Sweat osmolality
Shwachman score
The Shwachman score gives an indication of the degree and severity of chronic illness. Normal individuals would be expected to have values greater than 85; however, a low score is not specific for cystic fibrosis. The nine individuals with equivocal chloride results spanned the range from normality to severe chronic illness (Table 1) . Based on our own data we classified less than 150 mmol/kg as normal, greater than 200 mmol/kg as abnormal, and the region between as equivocal.
Sixteen patients in the control group with normal chloride and equivocal or abnormal sodium results had osmolality measured, with results ranging from 125-190mmol/kg. Osmolality in this group reflected the sodium level and did not give the increased discrimination of chloride levels. All 16 patients had normal Schwachman scores and none was considered clinically to have cystic fibrosis.
Of the patients with equivocal chloride results (Table I) , none had a normal osmolality, two (patients 4 and 7) had equivocal results, and the remainder were abnormal. Osmolality reflected the sum of sodium and chloride, and therefore provided no more discrimination than chloride alone.
Fludrocortisone suppression test This test was used occasionally in patients presenting in adult life. Patient 4 (Table 1) who presented with steatorrhoea and chest infections aged 25 years, showed no suppression of sweat sodium or chloride after 5 mg fludrocortisone daily for 2 days. She would be classified as normal according to the sum of her sodium and chloride, but abnormal according to their ratio.
DNA haplotyping Of the 112 cystic fibrosis patients whose sweat chloride was greater than 70 mmol/L, 50070 were homozygous for deletion of phenylalanine at position 508 (~F508) on the cystic fibrosis gene DISCUSSION Shwachman described age-related changes in sweat electrolytes in a large study in the 1960s,12 but found no overlap between normal and cystic fibrosis populations at any age. A more recent publication? suggests that particularly for sweat sodium a degree of overlap occurs which is sufficient to lead to diagnostic difficulties if the same criteria are used as for children. This study demonstrates the progressive amount of overlap found with increasing age is the result of the different age dependency of sodium and chloride, and the changes in that dependency with age. The increase in sweat sodium with age in normal children under the age of 12 years confirms our earlier findings based on the population referred for sweat tests. The greater number of older patients in this study shows that the increase with age does not occur for subjects over 12 years. This age-related difference is less marked for sweat chloride, and is coupled with a wider separation of the two populations at all ages, resulting in greatly improved discrimination of the two populations when sweat chloride is measured.
In common with many British laboratories we previously measured sodium alone. Introduction of chloride measurements was delayed because the automated colorimetric method used for plasma chloride analysis was insufficiently sensitive to the low concentrations found in normal sweat samples. Dilution of sweat samples with a solution of known chloride concentration has been proposed to produce readings within the analyser working range," but in our assessment this gave results of insufficient accuracy and precision to be acceptable. Any restandardization of automated analysers to allow analysis of sweat samples is timeconsuming and means the analyser cannot be concurrently used for urgent analyses. Our solution was to introduce a separate manual colorimetric assay for sweat chloride measurement alone.
Various combinations of sodium and chloride have been proposed to improve discrimination in borderline cases.l-'? Plotting sodium against chloride clearly shows patients with normal chloride and equivocal or abnormal sodium as belonging to the normal population. However, patients with equivocal chloride results could not be clearly assigned to either population. As previously reported.!? cystic fibrosis patients usually had a lower sodium/chloride ratio than normal. More of our younger patients had lower sodium than chloride concentrations, and the ratio increased with age, as might have been predicted from the greater age dependency of sodium. Applying the ratio to the nine equivocal patients was no more helpful than the chloride result alone. The suggested distinguishing level of 140 for the sum of sodium and chloride! was equally unhelpful for the same reasons, as was the measurement of osmolality. No consistent classification of the nine equivocal patients could be achieved using these methods.
We have now abandoned routine osmolality measurements on Wescor sweat tests in favour of chloride. Osmolality measurements were timeconsuming for laboratory staff, and their significance was poorly understood by clinicians. Although we have no direct experience of sweat conductivity measurements, on theoretical grounds they would also be expected to reflect the sum of sodium and chloride, and so give less discrimination than chloride alone.
Interpretation of fludrocortisone suppression tests also poses problems. The result on patient 4 is equivocal when interpreted according to Hodson," because there was no suppression of an equivocal baseline sodium. All patients with an equivocal initial result must inevitably give an equivocal or normal result post suppression. This test can therefore exclude a diagnosis of cystic fibrosis if suppression into the normal range is achieved but cannot provide evidence in support of a diagnosis in cases where the baseline sodium result is equivocal. In addition it depends absolutely on patient compliance. Patients who do not take their fludrocortisone will show lack of suppression, the result expected in cystic fibrosis cases. Reference data is not available for chloride in this test. Our experience suggests that most older patients with equivocal or even abnormal sodium results have a normal baseline chloride result, making further tests unnecessary.
The combination of DNA haplotyping and sweat chloride measurement proved invaluable in reversing the diagnosis of cystic fibrosis in some subjects. Sixteen patients, whose diagnostic sweat tests had measured sodium alone, were apparently well but still attended the cystic fibrosis clinic. On repeat sweat testing all had normal chloride results with equivocal or abnormal sodium concentrations. DNA studies, carried out with the linked probes then available, XV2c and KM19, showed that all had haplotypes found in less than 1010 of the cystic fibrosis population. Evidence from two independent sources in addition to clinical reassessment therefore provided the basis for reversing the diagnosis of cystic fibrosis in these patients.
Using a direct oligonucleotide probe for thẽ F508 mutation it was apparent that the group with equivocal chloride results were not typical of the cystic fibrosis population, none having the FF genotype found in > 50% of cystic fibrosis patients." Equally they were quite distinct from the control population in whom, assuming a carrier frequency of one in 25, greater than 96% would be expected to have the genotype NN. Further investigation on these patients for other mutations in the cystic fibrosis gene is still being carried out.
Earlier work on sweat electrolytes in cystic fibrosis carriers produced conflicting results, some studies finding a significant increase in sweat chloride in parents of cystic fibrosis patients;'? and others reporting no significant increases in parents and siblings of cystic fibrosis patients compared to control groups." Before the identification of mutations in the cystic fibrosis gene these were the only identifiable groups available for study as obligate heterozygotes, or at a two in three risk of being carriers for cystic fibrosis, and this greatly limited studies on heterozygous individuals. It is possible that some of the clinically well subjects in our equivocal group may represent the upper limit of the expected range for cystic fibrosis heterozygotes, This group contained several patients referred to the specialist clinic who had presented with a suggestive clinical picture. Their diagnostic sweat tests were abnormal 6-25 years ago, when sodium alone was measured. This group includes patients who had posed diagnostic difficulties over many years, and can be considered to be highly selected.
Several of these patients remain without a definitive diagnosis, and none has as yet been discharged from the cystic fibrosis clinic.
A recent report on sweat testing in adults? found no equivocal chloride results in cystic fibrosis patients, and one in a subject with chest disease. The greater number of equivocal patients in our study may be ascribed to the larger number of patients studied, and also to the selection of all patients attending the clinic including a highly selected group of patients who posed diagnostic difficulties. Defining a single cutoff value for sodium and chloride, as recommended by Hall et al.,9 could be misleading. Several of our equivocal group had chloride results very close to 60 or 70 mmollL, such that a repeat sweat test might reasonably have been expected to give a result on the other side of that level, due to experimental and biological variation.
We would expect with more intensive investigation of new patients, and review of those who have previously given equivocal results, that the number of patients in the borderline sweat test group will grow. DNA studies using all probes currently available are mandatory in these patients. As more mutations within the cystic fibrosis gene are described associated with disease of varying severity it may be necessary to revise diagnostic criteria based on sweat test results. Variant forms of cystic fibrosis associated with a milder clinical picture and less elevation of sweat electrolytes might be expected to present at an older age than the majority of patients with the FF genotype.
A reliably performed sweat test by an experienced operator will continue for some time to be the cornerstone of diagnosis of cystic fibrosis. Indeed current estimates of the frequency of different mutations in the cystic fibrosis gene are absolutely dependent on the diagnosis of cystic fibrosis being correct, and this places great responsibility on the sweat testing service.
We recommend that both chloride and sodium are measured in all sweat tests, but that greater weight is given to the chloride result. We agree with Hall et aU that sweat chloride results of~70 mmollL are consistent with a diagnosis of cystic fibrosis at any age. We would more cautiously suggest the use of an equivocal range for chloride from 50-70 mmollL to allow referral of patients of all ages with consistently equivocal chloride results for further clinical assessment by an experienced cystic fibrosis physician. Sweat sodium results may not help in defining these patients. DNA studies with all probes currently available should be carried out before any final diagnosis is made. The number of identified mutations in the cystic fibrosis gene is continuing to rise rapidly. Although a definitive diagnosis may not be made immediately on atypical patients, stored DNA on these cases can be re-examined with new probes as they become available. The opportunity to collect DNA samples should therefore not be missed.
